Serbian
Serbian
Abstract
Endometrial carcinomas (EC) represent the most common malignant tumors of the female reproductive system and the sixth most common in the female population with an increased incidence of morbidity and mortality over the past three decades. In addition to stage, grade and type of tumor are the most significant prognostic factors of the biological behavior of EC and in current clinical practice are based on pathohistological examination. The shortcomings of the current histological classification are cited as one of the key limiting factors in further research, as well as in the understanding of EC carcinogenesis and improving therapeutic protocols. A new molecular classification of EC was formulated, based on the analysis of molecular biological features, recognized as highly related to the specific clinical course. Considerable efforts have been made to understand the process of angiogenesis as one of the key processes in tumor growth. The vascular endothelial growth factor (VEGF) family is a group of proangiogenic ligands that play a central role in the process of physiological and pathological angiogenesis. VEGF is the most widely investigated angiogenic factor as a potential biomarker and target for targeted therapy. After vast research, clinical studies have shown significant advances in the development of anti-angiogenic therapy directed at VEGF, predominantly in the form of combined therapy. In defining therapeutic groups, this therapy relies on the molecular classification of EC. Antiangiogenic therapy is limited to small specific groups of patients, is associated with side effects, and many patients who initially responded to targeted therapy develop resistance over time, which indicates the further need for a better understanding of the mechanisms and factors involved in the angiogenic process of EC. Potentially promising advances in the development of targeted therapeutic options for EC can be expected within the integration of molecular features of EC as a factor in the context of histological classification.
References
1. American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021. 1–72. (Suggested citation)
2. Herrington CS, (ed.). Editorial Board WHOCOT.WHO Classification of Tumours Female Genital Tumours. 5th ed. International Agency for Research on Cancer, 2020.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 ;15(1):10-7.
4. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543-51.
5. Miyamoto T, Shiozawa T. Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor. Gynecol Endocrinol. 2019;35(5):370-5.
6. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012 ;120(2 Pt 1):383-97.
7. Buhtoiarova TN, Brenner CA, Singh M. Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. Am J Clin Pathol. 2016 ;145(1):8-21.
8. Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019 ;38 Suppl 1:S64-S74.
9. Saimi M, Moriya S, Li ZL, Miyaso H, Nagahori K, Kawata S, et al. Cytonuclear Estrogen Receptor Alpha Regulates Proliferation and Migration of Endometrial Carcinoma Cells. Tokai J Exp Clin Med. 2021 ;46(1):7-16.
10. Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol. 2016;141(2):312-7.
11. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 ;399(10333):1412-28.
12. Roškar L, Roškar I, Rižner TL, Smrkolj Š. Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer. Biomolecules. 2021;12(1):7.
13. Holland CM, Day K, Evans A, Smith SK. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer. 2003;89(5):891-8.
14. Weston G, Rogers PA. Endometrial angiogenesis. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(6):919-36.
15. Berger AA, Dao F, Levine DA. Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives. Gynecol Oncol. 2021 ;160(3):844-50.
16. Dziobek K, Opławski M, Grabarek BO, Zmarzły N, Tomala B, Halski T, et al. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. Curr Pharm Biotechnol. 2019;20(11):955-63.
17. Saarelainen SK, Staff S, Peltonen N, Lehtimäki T, Isola J, Kujala PM, et al. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol. 2014 ;35(5):4651-7.
18. Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, Berezowska A, Radziszewski J, Bidzinski M, et al. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients. PLoS One. 2017;12(10):e0184576.
19. Lee SY. Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer. Biomed Res Int. 2021; 2021:2068023.
20.Park J., Lee J, Lee Y, Shim S, Suh D, Kim J. Major clinical research advances in gynecologic cancer in 2021. J Gynecol Oncol. 2022;33(2):e43.